Drug discovery has always been a numbers game, but it is an unusually expensive one. Researchers can spend more than a decade and billions of dollars moving a potential medicine from an early idea to a treatment that can reach patients. The problem is not simply a lack of scientific knowledge. It is the sheer number of possibilities that must be searched, tested and rejected.
This is where the role of AI in drug discovery processes comes into play. Instead of depending mostly on trial and error processes, scientists can utilize AI technology to search through biological information, prioritize targets, screen molecules, develop new ones, and identify risks sooner than later. In this article, we will explore the places where this happens and, even more importantly, where human confirmation is needed.
The Core Bottlenecks in Traditional Drug Development
The hardest part of drug discovery is not finding one molecule that works. It is finding one that works well enough, safely enough and consistently enough to justify the next expensive experiment.
Human biology creates an enormous search problem. Genes, proteins, pathways, cells and diseases interact in ways that are difficult to isolate experimentally. Chemical space creates another problem. Researchers can explore only a fraction of the possible molecules through physical experiments, which means promising options can remain buried among enormous numbers of possibilities.
The scale becomes clearer with Google DeepMind’s AlphaGenome Atlas. It contains predictions for the molecular effects of 9 billion single-nucleotide variants, covering every possible single-letter change in the human genome. Google DeepMind says experimentally testing all of these possibilities would be practically impossible.
This is the core opportunity for the AI in drug discovery process. AI does not remove biological complexity. It helps researchers decide where to look first.
5 Ways AI Is Reshaping the Drug Discovery Process
1. Target Identification and Disease Modeling
A drug can only work against a useful biological target. Finding that target, however, often means connecting evidence scattered across genomics, proteomics, clinical data, scientific literature and other biological datasets.
AI can piece together these diverse sources of data and reveal patterns which would not necessarily be recognizable by researchers themselves. Algorithms such as machine learning methods, neural networks and graph structures can connect biological pathways and/or genes with specific clinical outcomes and create hypotheses which would be tested in laboratory settings. This means that AI takes on an important part before any molecule has even been designed.
The practical impact can be significant. One company interviewed by the OECD described an AI-powered target discovery engine that identified 7 novels, first-in-class targets within one year, compressing work that traditionally took several years into a single R&D cycle. This is a company-reported result presented by OECD, not an independently validated OECD measurement.
The bigger shift is from asking researchers to search harder to helping them search smarter.
2. AI-Powered Virtual Screening
Once a target is identified, researchers still face another enormous problem. Which molecules should actually be tested?
Traditional screening can require laboratories to examine large chemical libraries through physical experiments. That process consumes time, materials and scientific resources, while most candidates will eventually fail. AI-powered virtual screening changes the sequence by allowing researchers to evaluate molecules computationally before committing to every wet-lab experiment.
AI models can predict how candidate molecules may interact with biological targets and rank compounds according to characteristics that matter for further development. This does not mean the computer has proved that a molecule will become a drug. It means researchers can narrow the list before spending significant resources on laboratory testing.
Also Read: What Is Autonomous Vehicle Sensor Technology and How Does It Enable Safer Self-Driving Vehicles?
That distinction is central to the AI in drug discovery process. The technology is most useful when it improves the quality of the shortlist, not when it pretends the shortlist is the final answer.
It also creates a feedback loop. Experimental results can feed back into models, helping researchers refine future predictions and progressively improve how they search chemical space.
3. Generative Molecular Design
Virtual screening asks which existing molecules deserve attention. Generative molecular design asks a more interesting question. What if the right molecule has not been designed yet?
Generative AI can learn patterns from chemical and biological data and produce new molecular structures with desired characteristics. Instead of searching only through an existing library, researchers can define constraints around properties such as target affinity, solubility, toxicity and synthesizability and allow algorithms to explore possible candidates.
That is one of the most important developments in the AI in drug discovery process because it changes the role of AI from a filter into a design partner.
A useful example comes from Sanofi’s CodonBERT. OECD reports that the LLM was trained on 10 million mRNA sequences and reportedly halved mRNA design time. The result should be treated as a reported company outcome rather than a universal benchmark for AI drug design.
The real advantage is not simply speed. It is the ability to explore molecular possibilities that researchers may not have considered manually.
4. Lead Optimization
Finding a promising molecule is only the beginning. A candidate that binds strongly to a target can still fail because it is unstable, poorly soluble, difficult to manufacture or potentially toxic.
Lead optimization is therefore a balancing act. Improving one property can damage another. Increasing potency may affect solubility. Changing the structure to improve stability may reduce activity. Making a molecule easier to manufacture may introduce another trade-off.
AI can help researchers manage these competing objectives simultaneously. OECD notes that generative design workflows can iterate lead series while considering potency, toxicity and manufacturability together.
This makes the AI in drug discovery process less about finding a single ‘perfect’ molecule and more about navigating a complicated set of trade-offs.
The practical benefit is fewer blind synthesis cycles. Researchers can prioritize compounds that already appear to satisfy several important requirements, then use laboratory results to refine the next generation.
5. Toxicity Prediction and Safety
A drug candidate that works against its intended target but causes serious harm is not a successful candidate. Safety therefore needs to enter the discovery process much earlier.
AI can analyze historical biological, chemical and preclinical data to identify patterns associated with potential toxicity. It can also help predict molecular interactions and flag candidates that may be more likely to fail later.
That makes toxicity prediction an important part of the AI in drug discovery process, because safety is not something researchers can afford to bolt onto the workflow at the end.
Still, prediction is not proof. The model might be able to identify a possible threat, but scientists have to establish if the threat actually exists, how important it is, and whether the chemical could be changed to make it less of a danger. That is why the best AI workflow uses predictions to choose which cases deserve experimental testing.
Real-World Impact and the 2026 Outlook
The most interesting 2026 developments are not showing that AI can simply replace laboratories. They are showing how AI can improve the questions researchers take into those laboratories.
Google DeepMind reports that Stanford researcher Gary Peltz used Co-Scientist to search for existing medicines that could potentially be repurposed for liver fibrosis. Co-Scientist proposed 3 candidates. When all five candidates, including two selected independently by the researcher, were tested using live human liver cells, 2 of the 3 AI-selected candidates blocked fibrosis and promoted liver-cell regeneration, while the researcher’s two selections showed no benefit in that test.
That result is interesting for a reason beyond the numbers. It shows the emerging model of AI-assisted research in practice. The system searched a huge body of scientific knowledge, generated candidates and surfaced connections that were easy to miss. The laboratory then tested whether those ideas held up biologically.
This is where the AI in drug discovery process needs to be understood properly. AI can compress search and prioritization, but it does not eliminate validation. Google DeepMind describes Co-Scientist as a research partner, not a replacement for scientific or clinical expertise.
That distinction will matter even more as AI systems become capable of generating more hypotheses, molecules and experimental plans. The bottleneck may gradually move away from generating possibilities and toward deciding which possibilities deserve trust.
Conclusion
The most important change brought by the AI in drug discovery process is not that machines are suddenly discovering medicines on their own. That framing misses the real shift.
AI is becoming a way to reduce the number of bad questions researchers have to spend time answering. It can search biological data, prioritize targets, screen compounds, generate new designs and identify potential risks before researchers commit to another expensive experiment.
But the industry should resist the temptation to confuse prediction with proof. A model can narrow the field. A laboratory still has to establish whether the biology holds up.
WHO’s 2026 work makes the broader principle clear. AI can expand the evidence researchers can analyze, while human judgement remains responsible for interpreting evidence and making decisions.
The future of drug discovery is therefore unlikely to be human versus AI. It is more realistically human expertise operating with a far more powerful search and reasoning layer.
Frequently Asked Questions
How much time does AI save in the drug discovery process?
There is no single time-saving figure that applies across the entire AI in drug discovery process. Results vary by task, model, dataset and stage of development. OECD reports that Sanofi’s CodonBERT reportedly halved mRNA design time, while another company described compressing target-discovery work that traditionally took several years into a single R&D cycle.
What is generative molecular design?
Generative molecular design uses AI to create or optimize new molecular structures according to defined properties and constraints. Instead of only screening existing chemical libraries, the AI in drug discovery process can use generative models to explore new candidates based on factors such as target affinity, solubility, toxicity and synthesizability.
Will AI replace human scientists in biopharma?
No. The more realistic role is that AI acts as an advanced navigator that helps human scientists search larger datasets, generate hypotheses and prioritize experiments. WHO describes AI as something that should augment rather than replace human judgement, with humans remaining responsible for interpreting evidence and weighing decisions.
